MedTrace Logo

Explicit Assessment of Thromboembolic Risk and Prophylaxis for Medical Patients in Switzerland

NCT01277536 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1478

Last updated 2014-03-18

No results posted yet for this study

Summary

Until now, no risk assessment model informing about the need of thromboprophylaxis in patients admitted for an acute medical event has been validated.

The goal of this project is to indirectly validate a model developed in Geneva by a non -interventional study involving the collection of patient characteristics during the hospitalization and a 3-month follow-up. These data will allow for the determination of the patient's risk, according to the Geneva model, and its validity, according the actual thrombo-embolic events, corrected for the thromboprophylaxis received.

The project is multicentric in Switzerland (5-10 centers) and should involve about 1000 patients.

First amendment (may 2011) : we have obtained the IRB approval for collecting data from patients who die during their hospital stay and for whom informed consent is not be possible to obtain.

Conditions

  • Venous Thromboembolism

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    collaborator OTHER

  • Kantonsspital Baden

    collaborator OTHER

  • University of Zurich

    collaborator OTHER

  • Luzerner Kantonsspital

    collaborator OTHER

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Mathieu R Nendaz, Dr · General Internal Medicine Division, University Hospitals of Geneva

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277536 on ClinicalTrials.gov